Ferroptosis Pathways in Neurodegenerative and Neuropsychiatric Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 139

Special Issue Editor


E-Mail Website
Guest Editor
Neurochemistry Laboratory, Department of Psychiatry-Neuroscience, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, Boston, MA 02129, USA
Interests: Alzheimer’s disease; Parkinson’s disease; long COVID; alpha-synuclein; amyloid precursor protein (APP) and their transcripts; brain iron homeostasis; iron-responsive elements; cytokine dysregulation; ferritins; iron; neurochemistry; neuropsychiatric disorders; neurotoxicity, heavy metal toxicity to neurons

Special Issue Information

Dear Colleagues,

Ferroptosis is a newly discovered pathway towards programmed cell death. It is caused by an excess of free intracellular iron that leads to cytotoxic lipid (hydro-) peroxidation. Ferroptosis involves various processes in biology, such as transcriptional and RNA-mediated controls of iron metabolism, lipid metabolism, oxidative stress, and biosynthesis of glutathione (GSH), as well as nicotinamide adenine dinucleotide phosphate (NADPH) and coenzyme Q10 (CoQ10). Erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants, including those generated by iron-associated radicals. A growing body of evidence suggests that perturbations of iron homeostasis play a key role in the occurrence and development of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and vascular dementia, which suggests that ferroptosis may be involved in regulating the progression of not only neurodegenerative but also neuropsychiatric diseases.

The Special Issue welcomes reviews, as well as original in vivo, in vitro, and preclinical research focused on the regulatory mechanism of ferroptosis and its various effects in neurodegenerative diseases, in order to provide a reference for the research on ferroptosis in neurodegenerative and neuropsychiatric diseases.

Dr. Jack T. Rogers
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ferroptosis
  • iron
  • Alzheimer's disease
  • Parkinson’s disease
  • neurodegenerative diseases treatment
  • neuropsychiatric diseases
  • long COVID

Published Papers

This special issue is now open for submission.
Back to TopTop